Introduction
Myeloid leukemia, a type of leukemia involving myeloid tissue, is a heterogeneous group of clonal disorders characterized by an abnormal proliferation of myeloid stem/progenitor cells and subsequent bone marrow failure. Although a majority of these patients can achieve complete remission by current chemotherapies, most of these patients may ultimately relapse within a certain limited period. Hence, there is a largely unsatisfied need for more effective drugs for the patient population with treatment failure or relapse.
Homoharringtonine (HHT), a kind of Chinese traditional medicine, is a compound derived from the Cephalotaxus genus. 1 HHT was first isolated in the 1970s and was found to have natural antitumor and antileukemic activities in in vitro and in vivo studies. 2, 3 HHT was initially considered as one of the most effective choices for patients with acute myelocytic leukemia (AML) and chronic myelogenous leukemia (CML) who failed with interferon alpha (IFN-α) therapy and could not tolerate hematopoietic stem cell transplantation. 4, 5 However, after the tyrosine kinase inhibitor imatinib mesylate was recommended as the standard therapy for patients with CML, 6 the attention toward HHT began to decrease. 7 Recently, a few encouraging findings demonstrated that HHT played a critical role in the treatment of patients who failed with imatinib therapy, especially those with tyrosine kinase inhibitor-insensitive T315I mutation.
According to prior studies, HHT exerts functions probably in a unique way. HHT induced apoptosis of human myeloma cell lines by activating caspase-3 and mediating cleavage of poly-ADP-ribose polymerase (PARP). In addition, the expression of Bax is upregulated while that of Bcl-2 is slightly decreased. 9 Lou et al 10 demonstrated HHT-induced apoptosis through intrinsic and extrinsic apoptotic pathways, including the activation of caspase-3, caspase-8, caspase-9, and PARP. HHT may also inhibit the synthesis of short-lived proteins by targeting the A-site cleft of eukaryotic ribosomes. 11 The myeloid cell leukemia-1 (Mcl-1) protein, a member of antiapoptotic Bcl-2 family proteins, is one of such short-lived proteins that are highly expressed in leukemia cells. 12 As a promising antitumor agent, HHT, which is hydrophobic, must be formulated in solvents to increase the solubility and bioavailability. Unacceptable cardiovascular adverse events, including hypotension and tachycardia, may occur when patients are treated with HHT at a dose of 5 mg/m 2 or 6 mg/m 2 daily. 13, 14 However, the efficacy of drugs is usually associated with dose-and duration-dependent side effects. With the rapid development of nanoscience, people started drawing attention to nanotechnology for cancer therapy and drug delivery for the purpose of enhanced drug accumulation and reduced dose. 15 Recent reviews promised a broad prospect for nanotechnology as a fundamental tool in cancer research. 16, 17 In addition, polymer nanospheres and nanoparticles (NPs) have been increasingly proved to enhance the drug delivery efficiency to target cells. 18, 19 By coloading with NPs, the increased solubility, decreased side effects, and extended availability in circulation were observed for chemotherapeutic agents. With the NPs, drug particles can be dispersed to increase the half-life in the blood and prevent protein from adsorption. Nanoparticle albumin-bound (nab) paclitaxel, a novel product in the NP field, combines paclitaxel with biologically interactive human albumin. 17 In patients with breast cancer, the nab paclitaxel demonstrated higher antitumor activity and clinical efficacy when compared with solvent-based paclitaxel. 20 Choosing magnetic Fe 3 O 4 nanoparticles (MNP-Fe 3 O 4 ) as a drug delivery vector, we developed HHT-MNP-Fe 3 O 4 to improve the therapeutic effect on myeloid leukemia cells and investigated its biological effects. MNP-Fe 3 O 4 increased HHT sensitivity against myeloid leukemia cells by inducing apoptosis through the caspase-3 and PARP pathway. Furthermore, the animal studies also confirmed its remarkable antitumor activity in mice. Our study demonstrates the potential of HHT-MNP-Fe 3 O 4 as an effective strategy for myeloid leukemia and more hematological malignancies in the clinic.
Materials and methods cell culture
The myeloid leukemia cell lines HL60, K562, NB4, and SHI-1 were obtained from the Shanghai Cell Culture Institute (Shanghai, People's Republic of China). All but SHI-1 cell lines were cultured in RPMI-1640 (SHI-1 cell line in Iscoves modified Dulbecco medium), containing 100 U/mL penicillin and 10% fetal bovine serum. All cell lines were incubated in a humidified atmosphere containing 5% CO 2 at 37°C. Total viable cells were assessed using the trypan blue staining. 
Materials

Preparation of hhT-MNP-Fe 3 O 4
A two-step method reported previously was used for the synthesis of oleic acid-coated iron oxide NPs. 21 HHT and oleic acid-coated iron oxide NPs were dissolved in tetrahydrofuran at a ratio of 1:5 (w/w) for preparation of HHT-MNP-Fe 3 O 4 . The mixture was slowly added into 1% polyoxyethylene-polyoxypropylene copolymer solution under sonication, and the resulting suspension was stirred for 6 hours to evaporate tetrahydrofuran. Finally, the resulting suspension was filtered and lyophilized. The drug loaded in MNPFe 3 O 4 was 10.71 wt% (HHT-to-iron weight ratio). The free drug was separated from loaded drug by retrodialysis method and quantified by high-performance liquid chromatography. 22, 23 The morphology of MNP-Fe 3 O 4 after rehydration was observed using a transmission electron microscope. The hydrodynamic diameter and size distribution of MNP-Fe 3 O 4 were examined using a dynamic light scattering instrument and analyzed by The treatment was carried out three times without interval in 3 days by the tail vein. Tumor volume was measured at days 7, 14, 21, and 28 to evaluate the drug effect. At day 28, mice were killed and the tumors were fixed in 10% neutral formalin, desiccated, and then embedded in paraffin for hematoxylin-eosin (HE) staining. This assessment was performed by independent microscopists. This study was approved by the ethics committee and Animal Care and Use Committee of the First Affiliated Hospital of Soochow University. All operations were performed according to the International Guiding Principles for Biomedical Research involving Animals 1985.
Mice leukemia model
Four-to five-week-old BABL/C mice were inoculated with EL9611, a murine erythroleukemia cell line. 16 A dose of 5×10 6 EL9611 cells was transplanted through tail vein injection. Then, mice were randomly divided into four groups. After 7 days, treatments were continued for 3 days as described previously. At day 14, the spleen tissues were excised from the mice, fixed with 4% paraformaldehyde solution, and embedded in paraffin for immunohistochemical analysis.
statistical analysis
Data were represented as mean ± SD of three independent experiments. 
Results
Physicochemical and properties of hhT-MNP-Fe 3 O 4
As shown in Figure 1A , the polymeric micelles were generated by the hydrophobic interaction of the polyoxyethylenepolyoxypropylene copolymer chain and oleic acid on the surface of iron oxide NPs. The average core size of these HHT-NPs determined by transmission electron microscope was 11.2 nm ( Figure 1B) . The average hydrodynamic diameter of HHT-NPs for three batches determined by dynamic light scattering was 57.3±2.2 nm (Figure 1C ), which covered both the core-shell and its aqueous layer. Moreover, the polydispersity index of HHT-NPs is 0. 
Tumor-bearing animal models
The mean tumor volume for the mice treated with HHT-MNP-Fe 3 O 4 was significantly smaller than that with HHT alone (193±26 mm 3 versus 457±100 mm 3 , P0.05, Figure 5A ). The tumor weight for those with HHT-MNP- Figure 5D ). These results suggested that HHT-MNP-Fe 3 O 4 had higher antitumor activity than HHT in vivo.
Discussion
HHT, a natural cephalotaxine alkaloid, has been used in the People's Republic of China for treatment of leukemia for 30 years. As reported previously, HHT in combination with Ara-C could induce a complete remission rate of 39%-60% in elderly patients with AML. 24, 25 In a recent randomized Phase III trial (ChiCTR-TRC-06000054), HHT combined with cytarabine and aclacinomycin resulted in a CR rate of 73%, whereas HHT combined with cytarabine and daunorubicin in young patients with newly diagnosed AML resulted in a CR rate of 67%. 26 Because of its dramatic toxicity, the use of HHT is limited in the treatment of severe diseases. Moreover, the poor solubility results in poor bioavailability and low absorption of HHT. Meanwhile, the NPs can act as a universal drug carrier system for systemic administration of water-insoluble anticancer drugs. So, we chose MNP-Fe 3 O 4 as a drug delivery vector for HHT, aiming to increase its antitumor activity in vitro and in vivo. The effect of growth inhibition of HHT-MNP-Fe 3 O 4 was stronger than that of HHT alone as demonstrated by the significant difference between the two groups in cell proliferation and apoptosis. Apoptosis is triggered from the activation of caspases, including caspase-3, caspase-8, and caspase-9, which were situated at several key positions in the apoptotic pathways. 27 PARP, as one of the essential substrates, was activated by caspase-3 and caspase-7, which promoted the DNA strand breaks. 28 Mcl-1, as a representative prosurvival protein of the Bcl-2 family, protects tumor cells from apoptosis in the setting of hematologic malignancies. 29, 30 HHT is a molecule targeting the A-site cleft of eukaryotic ribosome, which then results in the decreased expression of Mcl-1. The toxicity of HHT-MNP-Fe 3 O 4 may cause some concern. However, in most studies about its in vivo toxicity, Fe 3 O 4 NPs have been shown to be associated with low toxicity in the human body. It is primarily due to the fact that they can be degraded and cleared from circulation by the endogenous iron metabolic pathways. Iron released from NPs is metabolized in the liver and subsequently used in the formation of red blood cells or excreted via kidneys. 31 A study comparing several metal oxide NPs demonstrated iron oxide NPs to be safe and noncytotoxic 100 mg/mL. 32 Another study on normal, glial, and breast cancer cells revealed that the toxicity of Fe 3 O 4 NPs coated with a bipolar surfactant is concentration dependent, with the particles being nontoxic in the concentration range of 0.1-10 mg/mL, whereas cytotoxic at 100 mg/mL. 33 Therefore, it is possible to find a safe concentration range for Fe 3 O 4 NPs without triggering adverse cellular response.
Conclusion
We designed a drug delivery vector for HHT. HHT-MNP- Here, we pay attention to the potential of MNP-Fe 3 O 4 and HHT, which can enhance the antitumor effect, and hope the designed anticancer drugs based on this research can be used in future clinical practice. Moreover, our study may provide a promising platform of the codelivery system as a component of combination therapy in the treatment of hematological malignancies.
